Advances in Treatment of Wilson Disease
Authors:
Open Access
- 28 February 2018
- journal article
- review article
- Published by Ubiquity Press, Ltd.
- Vol. 8, 525
Abstract
Background: Wilson disease (WD) is an inherited neurometabolic disorder that results in excessive copper deposition in the liver and the brain, affecting children and young adults. Without treatment the disease is invariably fatal. Though treatments for WD have been available since the 1950s, the disease continues to be associated with considerable morbidity and mortality because of missed diagnosis, and delayed or inadequate treatment. In this paper we survey WD-related literature in order to review recent advances in WD treatment. Methods: We performed a literature search using the PubMed database for articles relating to WD and its medical treatment. We reviewed the articles, and cross-references of relevant articles, to summarize the current practices for treatment of WD. Results: The survey shows that if WD is properly treated, in most patients the liver can be stabilized, even severe neurological disability reversed, and patients can resume normal lives. Discussion: Medical treatment for WD includes use of copper chelators (penicillamine, trientine, dimercaprol, dimercaptopropane sulfonate, and ammonium tetrathiomolybdate) and drugs that decrease gastrointestinal copper absorption. Our knowledge of the treatment approaches has benefited from the large systematic clinical studies that have been conducted over the last decade. For each drug used to treat WD, we surveyed its development, indication for use, dosing, efficacy, and adverse effects.Keywords
This publication has 155 references indexed in Scilit:
- Long-term exclusive zinc monotherapy in symptomatic Wilson disease: Experience in 17 patients #Hepatology, 2009
- A novel Global Assessment Scale for Wilson's Disease (GAS for WD)Movement Disorders, 2009
- Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King’s College Hospital and review of the literatureEuropean Journal of Pediatrics, 2008
- Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamineGut, 2001
- Successful medical treatment of severely decompensated Wilson diseaseThe Journal of Pediatrics, 1996
- D-Penicillamine—Iduced Myasthenia Gravis: Diagnosis Obscured by Coexisting Chronic Obstructive Pulmonary DiseaseThe American Journal of the Medical Sciences, 1995
- The Use of Trientine in Preventing the Effects of Interrupting Penicillamine Therapy in Wilson's DiseaseNew England Journal of Medicine, 1987
- Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimensHepatology, 1987
- Neurological Abnormalities in Wilson's Disease Are ReversibleNeuropediatrics, 1987
- The Antipyridoxine Effect of Penicillamine in Man*Journal of Clinical Investigation, 1964